News

As identified by the ALS Canada Research Team, here are the most newsworthy research stories of 2021 and a look ahead to 2022 with hope for what is to come.   A possible third treatment for ALS under review by…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada’s advocacy efforts as well as relevant developments within government. Please note that because ALS Canada advocates federally and provincially within Ontario,…

The province of Prince Edward Island (PEI) has listed Radicava (edaravone) on the public formulary under Special Authorization as a treatment for ALS. With this announcement, all provinces and territories across Canada – as well as Veterans Affairs Canada and…

Toronto, ON – The in-home support that the ALS Society of Canada provides to people living with ALS is highly valued by the community it serves and is something it had to evolve after the pandemic made physical distancing a public…

Update: July 7, 2022: Following Health Canada’s approval of ALBRIOZA (AMX0035) under a Notice of Compliance with Conditions (NOC/c), CADTH posted reimbursement recommendations for ALBRIOZA (AMX0035) in late June. ALS Canada provided feedback on the recommendations, bringing forward the perspectives…

Make your voice heard! The Canadian Agency for Drugs and Technology in Health (CADTH) has posted a call for patient input on AMX0035. ALS Canada will be preparing a submission reflecting the perspectives of the ALS community and we are…

November 1, 2021 – The Phase 3 VALOR results for tofersen did not show a statistically significant change in disease progression as assessed by the ALSFRS-R scale, however a number of other outcome measures suggested the treatment was able to…

ALS researchers from around the world continue to build upon existing work and make new discoveries in the hopes of realizing a future without ALS. In the October 2021 Research Update, you’ll learn about the progress researchers have made in…